• BX Home
  • Multiple Sclerosis: News [Page 14]

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is an autoimmune condition that attacks the central nervous system. This topic tracks information on multiple sclerosis treatments and the financial impact on companies researching and developing new drugs to fight this terrible disease.

Multiple Sclerosis is part of Business Exchange, suggested by Steve McCarthy. This topic contains 967 news and 242 blog items. Read updated news, blogs, and resources about Multiple Sclerosis. Find user-submitted articles and reactions on Multiple Sclerosis from like-minded professionals.

News

Please add new articles to this topic

Dr. Donohue: Some Moles Are A Health Threatmore

are not likely to die from an atypical nevus. Q: About 60 years ago, my friend died from multiple sclerosis.

Teva Announces Webcast on Results from Phase III ALLEGRO Study of Oral...more

Phase III ALLEGRO study of laquinimod, an investigational, oral, once- daily, immunomodulator for the treatment of...

Biogen MS Pill Meets Goals of Studymore

Biogen Idec Inc.'s oral drug for multiple sclerosis showed success in the first of two large clinical trials, moving...

Biogen Idex MS Drug Meets Study Goals, Stock Risesmore

A Phase 3 trial of Biogen Idec Inc.���s multiple sclerosis treatment BG-12 met the primary endpoint of reducing the...

Stocks to Watch: NYSE Euronext, Level 3, Global Crossingmore

Medical Systems surged 32% to $29.55 in premarket trading. A Phase 3 trial of Biogen Idec���s multiple sclerosis...

Hallandale woman helps others cope with MSmore

the world to know, Tom Selleck is a very sexy man.Rappaport is also a 73-year-old living with multiple sclerosis, a...

U.S. Stocks Rise as Takeover Deals, Earnings Bolster Optimismmore

a portfolio hedge. Biogen Idec Inc. rallied 5.2 percent to $77.07. The worlds largest maker of multiple sclerosis...

Biogen's MS drug meets study goalmore

Biogen Idec's experimental multiple sclerosis drug met the main goal in the first of two important late-stage studies,...

UPDATE 3-Biogen MS drug meets main goal in late-stage studymore

percent amid optimism the drug, if approved will strengthen Biogen's position in the highly competitive market for...

NHS cuts deprive patients of vital physiotherapy servicesmore

chronic illnesses are facing fewer sessions and longer waiting times Patients with chronic illnesses such as cystic...

Adeona Pharmaceuticals to sell 1.7 million shares to institutional inv...more

treatment called reaZin, which treats symptoms of Alzheimer���s disease, and a drug called Trimesta, for treatment of...

Is Matt Lauer leaving the 'Today' show too?more

on. She has said that she wants to focus on the health of her husband, who has battled multiple sclerosis and cancer,...

Teva Announces Webcast On Results From Phase III ALLEGRO Study Of Oral...more

the Phase III ALLEGRO study of laquinimod, an investigational, oral, once-daily, immunomodulator for the treatment of...

EMD Serono's Commitment to Advance Multiple Sclerosis Care and Researc...more

Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple...

CORRECTING and REPLACING Biogen Idec to Report First Quarter 2011 Fina...more

in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its...

More evidence pregnancy is safe with MSmore

EDT NEW YORK (Reuters Health) - A new research review strengthens the evidence that women with multiple sclerosis are...

Biogen, Elan's Tysabri Label Updatedmore

The label of multiple sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan Corp., has been changed to include the...

Rosy-Cheeked Biotechsmore

investors earlier this week when the company said paid prescriptions had more than doubled for Acthar Gel, its multiple...

Genzyme Presents New Data From Alemtuzumab Phase 2 MS Trial At 63rd An...more

that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple...

Simple steps could cut drugs costs-Express Scriptsmore

rising 19.6 percent last year. Express Scripts estimated that specialty drugs -- including treatments for inflammatory...

Annual Report 2010 Active Biotech AB (publ)more

entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties...

Novartis Aims to Resurrect 'Zombie' Drugmore

a leukemia drug that brought in $4.3 billion, may face generic competition starting in 2015. The oral multiple...

Novartis Aims to Resurrect ���Zombie��� Drug in EU After Four Yearsmore

a leukemia drug that brought in $4.3 billion, may face generic competition starting in 2015. The oral multiple...

Karen Dust obituarymore

Our ex-colleague and friend Karen Dust, who has died aged 48 after suffering from a progressive form of multiple...

Report: Drug spending growth slowed in 2010more

by medical professionals. Express Scripts said 68 percent of specialty drug costs were on treatments for inflammatory...

Top Sources: Multiple Sclerosis

  • St. Petersburg Times
  • Reuters
  • Chicago Tribune
  • Mail Online UK
  • MarketWatch
  • BBC
  • Boston Globe
  • Philadelphia Inquirer
  • BusinessWeek
  • Seattle Times

Most Active Users in this Topic

see all contributors in Multiple Sclerosis

Featured White Papers

Post a Job

Jobs in this Topic

Director Specialty Distribution Multiple Sclerosis Genzyme | Cambridge, MA
Posted: Mar 29
RN/Registered Nurse Clinical Coordinator - Ambulatory Mulitple Sclerosis Center Rush University Medical Center | Chicago, IL
Posted: May 14
Multiple Sclerosis Nurse Educator Quintiles Transnational | Lansing, MI
Posted: May 20
Client in West Virginia Seeking Multiple Neurologist Alliance Recruiting Resources | West Virginia
Posted: May 24
Neurology - Multiple Sclerosis Physician Practicewisemd | Cincinnati, OH
Posted: Mar 30

Report comment contains invalid characters. ()
cancel
Search Cancel